Drugs / BI 1595043
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04789291 | May → Aug 2021 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT04789304 | Apr 2021 → Jan 2022 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT04439838 | Aug 2020 → Mar 2021 | — | Boehringer Ingelheim | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BI 1595043 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04789291 ↗ |
| Route | Oral | “following oral administration of single rising doses” NCT04439838 ↗ |